Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib in radiotherapy/chemotherapy-failed head and neck squamous cell carcinoma
ChiCTR2100052047Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wannan Medical College
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in head and neck squamous cell carcinoma (HNSCC), sponsored by The First Affiliated Hospital of Wannan Medical College. Primary endpoint: ORR. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100052047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052047.